Cortex Pharmaceuticals Inc. (CORX) Financials Nov
Post# of 250675
Posted On: 11/17/2014 3:27:35 AM
Cortex Pharmaceuticals Inc. (CORX) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Cortex Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 0 0 473,592 3.11M 48,309
Cost of Goods Sold (COGS) incl. D&A 10.78M 4.6M 3.74M 2.19M -
COGS excluding D&A 10.62M 4.41M 3.63M 2.08M -
Depreciation & Amortization Expense 164,890 186,940 112,475 106,971 115,862
Depreciation - - - - 26,383
Amortization of Intangibles - 0 0 - 89,479
Gross Income (10.78M) (4.6M) (3.27M) 926,910 -
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 4.26M 3.74M 4.55M 3.19M 2.66M
Research & Development - - - - 826,702
Other SG&A 4.26M 3.74M 4.55M 3.19M 1.83M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 4.61M
EBIT after Unusual Expense 0 0 0 0 (4.61M)
Non Operating Income/Expense 0 (123,177) 9.99M 0 (43,451)
Non-Operating Interest Income 443,061 16,580 - 6,947 92
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense - - 544,807 0 196,984
Gross Interest Expense - - 544,807 0 196,984
Interest Capitalized - - - - -
Pretax Income (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 -
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic 0 0 0 0 -
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Minority Interest Expense 0 0 0 0 0
Net Income (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Preferred Dividends 0 2.35M 0 0 0
Net Income Available to Common (14.6M) (10.79M) 1.63M (2.25M) (7.57M)
EPS (Basic) (0.31) (0.19) 0.02 (0.03) (0.07)
Basic Shares Outstanding 47.57M 55.78M 73.68M 79.99M 108.45M
EPS (Diluted) (0.31) (0.19) 0.02 (0.03) (0.07)
Diluted Shares Outstanding 47.57M 55.78M 73.69M 79.99M 108.45M
EBITDA (14.87M) (8.15M) (7.71M) (2.15M) (2.61M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Cortex Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 0 0 473,592 3.11M 48,309
Cost of Goods Sold (COGS) incl. D&A 10.78M 4.6M 3.74M 2.19M -
COGS excluding D&A 10.62M 4.41M 3.63M 2.08M -
Depreciation & Amortization Expense 164,890 186,940 112,475 106,971 115,862
Depreciation - - - - 26,383
Amortization of Intangibles - 0 0 - 89,479
Gross Income (10.78M) (4.6M) (3.27M) 926,910 -
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 4.26M 3.74M 4.55M 3.19M 2.66M
Research & Development - - - - 826,702
Other SG&A 4.26M 3.74M 4.55M 3.19M 1.83M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 4.61M
EBIT after Unusual Expense 0 0 0 0 (4.61M)
Non Operating Income/Expense 0 (123,177) 9.99M 0 (43,451)
Non-Operating Interest Income 443,061 16,580 - 6,947 92
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense - - 544,807 0 196,984
Gross Interest Expense - - 544,807 0 196,984
Interest Capitalized - - - - -
Pretax Income (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 -
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic 0 0 0 0 -
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Minority Interest Expense 0 0 0 0 0
Net Income (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (14.6M) (8.44M) 1.63M (2.25M) (7.57M)
Preferred Dividends 0 2.35M 0 0 0
Net Income Available to Common (14.6M) (10.79M) 1.63M (2.25M) (7.57M)
EPS (Basic) (0.31) (0.19) 0.02 (0.03) (0.07)
Basic Shares Outstanding 47.57M 55.78M 73.68M 79.99M 108.45M
EPS (Diluted) (0.31) (0.19) 0.02 (0.03) (0.07)
Diluted Shares Outstanding 47.57M 55.78M 73.69M 79.99M 108.45M
EBITDA (14.87M) (8.15M) (7.71M) (2.15M) (2.61M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)